Chesapeake Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Chesapeake Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-18,407	Closed	-$1.48M	–	69
2015 Q3	$1.48M	Hold	18,407	–	–	1.26%	29
2015 Q2	$2.21M	Hold	18,407	–	–	1.62%	23
2015 Q1	$1.92M	Hold	18,407	–	–	1.42%	30
2014 Q4	$1.78M	Sell	18,407 -6,893	-27%	-$639K	1.12%	39
2014 Q3	$1.98M	Hold	25,300	–	–	1.21%	36
2014 Q2	$1.6M	Buy	+25,300	New	+$1.5M	0.99%	40

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Chesapeake Asset Management's ALNY Position: Q4 2015 in Review

Chesapeake Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2015, closing a stake of 18,407 shares — an estimated $1.48M sold.

Chesapeake Asset Management first reported a position in ALNY in Q2 2014 and held it in 6 quarters. The position peaked at $2.21M in Q2 2015. 261 funds tracked by Wall St. Rank hold ALNY as of Q4 2015.

Chesapeake Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Chesapeake Asset Management sold 18,407 Alnylam Pharmaceuticals shares in Q4 2015, an estimated $1.48M.
Chesapeake Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2014 and held it in 6 quarters.
Chesapeake Asset Management's Alnylam Pharmaceuticals position peaked at $2.21M in Q2 2015.
261 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2015.

Based on Chesapeake Asset Management's 13F filing for Q4 2015, filed 10 Feb 2016.